Inactive Instrument

News iQX Limited

Equities

IQX

AU000000IQX4

Summary

Unlock all the news: Be the first to know and act before the market!

IQX : Continued Suspension - Non-payment of Annual Listing Fee 2022-2023	22-08-15	PU
IQX : Execution Of Deed Of Company Arrangement	22-08-05	PU
IQX : Outcome Of Creditors' Meeting	22-08-01	PU
IQX : Continued Suspension - Failure to lodge Half Yearly Financial Statements- 31 December 2021	22-03-16	PU
IQX : The phone number for the Voluntary Administrator was incorrect and nothing else has changed.	22-03-15	PU
IQX : seeks Voluntary Administration today to restructure	22-03-10	PU
IQX Limited Worldwide License for Harvard Uni's eRapid Technology	22-03-06	AW
IQX : Antisoma Therapeutics secures worldwide license for Harvard University’s eRapid technology for at-home diagnostic testing	22-03-06	PU
IQX : Director's declaration and undertaking on behalf of Vincenzo Milazzo	21-12-14	PU
IQX : Appointment/Resignation of Company Secretary	21-12-13	PU
IQX : FDA Breakthrough Devices Designation application to fast track rapid saliva glucose testing	21-12-12	PU
IQX Limited (NSX:IQX) FDA Breakthrough Devices Designation	21-12-12	AQ
IQX : Initial Director's Interest-Vincenzo Milazzo	21-11-24	PU
IQX : Final Director's Interest-John Stratilas	21-11-24	PU
IQX : Appointment of Director Vincenzo Milazzo and Resignation of Director John Stratilas	21-11-24	PU
IQX : Results of AGM FY2021	21-11-18	PU
IQX Chairman's Address to Shareholders AGM: 19 November 2021	21-11-18	PU
IQX Limited Wyss Validation Study SARS-CoV-2	21-11-10	AW
IQX Limited OncoTEX Gold Compound Licensing	21-11-04	AW
IQX : Filed a Pre-Submission package with the United States (US) Food and Drug Administration (FDA).	21-10-18	PU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News iQX Limited

Equities

IQX

AU000000IQX4

Summary

Filters